Cytori
Therapeutics CYTX has received the first $12 million
installment from the equity agreement with newly formed Lorem Vascular.
The equity agreement is part of Cytori's partnership announced earlier
this week with Lorem Vascular to commercialize Cytori Cell Therapy for
the cardiovascular, renal and diabetes markets in China, Hong Kong,
Malaysia, Singapore and Australia. Under the terms of the equity
agreement, Cytori will receive $24 million in exchange for 8 million
shares of Cytori common stock at $3.00 per share in two installments.
The second $12 million payment will be made before the end of the year.
Cytori's management will discuss the Lorem Vascular partnership today,
November 7, as part of its quarterly results
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in